Zydus Lifesciences has announced a proposal to buy back up to 95,65,217 equity shares, representing 0.95% of its total paid-up equity capital. The buyback will be conducted at a price of ₹1,150 per share, with a total outlay not exceeding ₹1,100 crore. This initiative will be executed through the tender offer route, with May 29, 2026, set as the record date to determine eligible shareholders.
Details of the Share Buyback
In a recent board meeting held on May 19, 2026, Zydus Lifesciences received approval for a share buyback program. The company intends to purchase up to 95,65,217 equity shares, which accounts for 0.95% of the total paid-up share capital. This strategic move aims to return capital to shareholders, reflecting the company’s robust financial position.
Pricing and Financial Impact
The shares will be acquired at a price of ₹1,150 per share. The total expenditure for this buyback is capped at ₹1,100 crore. This amount represents 5.16% and 3.84% of the aggregate of the company’s fully paid-up equity share capital and free reserves as of March 31, 2026, for standalone and consolidated financial statements, respectively.
Eligibility and Execution
The buyback will be conducted on a proportionate basis via the tender offer mechanism. All shareholders and beneficial owners, including promoters, who hold equity shares as of the record date are eligible to participate. The board has designated May 29, 2026, as the Record Date for identifying eligible participants. A dedicated Buyback Committee has been formed to oversee the process and manage all necessary actions to ensure the smooth execution of the program.
Source: BSE
